scholarly journals Gliosarcomas: A Rare Case Report at Viet Duc University Hospital and Review of the Literature

Author(s):  
Nguyen Thi Quynh ◽  
Nguyen Duc Hoan ◽  
Dao Thi Luan ◽  
Nguyen Tung Ngoc ◽  
Nguyen Sy Lanh

Gliosarcoma is a rare biphasic subtype of glioblastoma with the poor prognosis, principally affects adults; males are more frequently affected, with a male-to-female ratio of 1.8/1. Gliosarcomas are usually located in the cerebral hemispheres, involving the temporal, frontal, parietal, and occipital lobes in decreasing order of frequency. Rarely, gliosarcomas occur in the posterior fossa, lateral ventricles, or spinal cord. A case study: A 32-year-old woman presented with persistent nausea and headache. The preoperative diagnosis was Ependymoma in the right lateral ventricle of the brain. The patient underwent surgical resection of the tumor followed by external radiotherapy, and chemotherapy treatment. Histologic description: The tumor was made up of spindle cells with hyperchromic large nuclei and pink cytoplasm intermingled with large cells with markedly pleomorphic nuclei and abundant cytoplasm along with prominent mitotic activity. Tumour cells revealed positive staining for Ki67 (25%), Oligo2 (focal), GFAP (focal), SMA (focal); negative immunoreactivity for EMA, CD34, Bcl-2, TTF1. Pathological diagnosis: Gliosarcoma, grade IV. Conclusions: Gliosarcoma is an extremely rare neoplasm with an aggressive biological behavior. In terms of histopathology, gliosarcomas are characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation.   Keywords Gliosarcoma, glioblastoma multiforme, brain neoplasm. References [1] World Healh Organization, WHO Classification of Tumors of the Central Nervous System, International Agency for Research on Cancer (IARC) 69372 Lyon Cedex 08, France, 2016. [2] F. A. Hashmi, A. Salim, M. Shamim, M. Bari, Biological Characteristics and Outcomes of Gliosarcoma, The Journal of the Pakistan Medical Association, Vol. 68, No. 8, 2018, pp. 1273-1275. [3] P. Giglio, M. R. Gilbert, Encyclopedia of the Neurological Sciences (Second Edition), MA: Academic Press/Elsevier, Waltham, 2014. [4] R. K. Kevin, M. Anand, S. M. John, Adult Gliosarcoma: Epidemiology, Natural History, and Factors Associated with Outcome, Neuro Oncol, Vol. 11, No. 2, 2009, pp. 183-191, https://doi.org/10.1215/15228517-2008-076. [5] L. Han, X. Zhang, S. Qiu et al., Magnetic Resonance Imaging of Primary Cerebral Gliosarcoma: A Report of 15 Cases, Acta Radiologica, Vol. 49, No.9, 2008, pp. 1058-1067, doi:10.1080/02841850802314796. [6] D. N. Louis, H. Ohgaki, O. D. Wiestler et al., The 2007 WHO Classification of Tumours of the Central Nervous System, Acta Neuropathologica, Vol. 114, No. 2, 2007, pp. 97-109, doi:10.1007/s00401-007-0278-6. [7] L. Seth, P. Arie, I. James et al., Greenfield’s Neuropathology (Ninth Edition), CRC Press, Boca Raton, Florida, 2015. [8] L. Cervoni, P. Celli, Cerebral Gliosarcoma: Prognostic Factors, Neurosurgical Review, Vol. 19, No. 2, 1996, pp. 93-96, https://doi.org/10.1007/bf00418077. [9] J. Pardo, M. Murcia, G. Felip et al., Gliosarcoma: A Rare Primary CNS Tumor. Presentation of Two Cases, Reports of Practical Oncology & Radiotherapy, Vol. 15, No. 4, 2010, pp. 98-102, https://doi.org/10.1016/j.rpor.2010.05.003. [10] J. Lutterbach, R. Guttenberger, A. Pagenstecher, Gliosarcoma: A Clinical Study, Radiotherapy andOncology, Vol. 61, No. 1, 2001, pp. 57-64,https://doi.org/10.1016/S0167-8140(01)00415-7. [11] B. K. Kleinschmidt, T. Tihan, F. Rodriguez, Diagnostic Pathology: Neuropathology (Second Edition), Elsevier, Philadelphia, 2016. [12] H. F. Irwin, W. G. Sidney, Sarcoma Arising in Glioblastoma of the Brain, Am J Pathol, Vol. 31, No. 4, 1955, pp. 633-653. [13] A. S. Awadalla, A. M. A. Essa, H. H. A. Ahmadi et al., Gliosarcoma Case Report and Review of the Literature, The Pan African Medical Journal, Vol. 35, No. 26, 2020, https://doi.org/10.3109/02841869709001353.        

2021 ◽  
Vol 6 (6) ◽  
Author(s):  
Wang P ◽  
Wang J ◽  
Zou D ◽  
Pan J ◽  
Wu N

Background: Hemangiopericytomas (HPCs) with aggressive behavior are rare in the central nervous system and extremely rare in the sellar region. Here we presented a clinical case of HPC in sellar region.


Author(s):  
Paul Kleihues ◽  
Elisabeth Rushing ◽  
Hiroko Ohgaki

The revised fourth edition of the WHO classification of Tumours of the Central Nervous System, published in 2016, comprises several newly recognized tumour entities, and a significant restructuring of the classification, mainly based on genetic profiling. Glioblastomas are now classified into two major types. Isocitrate dehydrogenase (IDH)-wildtype glioblastoma (primary glioblastoma IDH-wildtype) develops rapidly de novo without a recognizable precursor lesion. IDH-mutant glioblastoma (secondary glioblastoma IDH-mutant) develops more slowly through malignant progression from diffuse or anaplastic astrocytoma. Medulloblastomas are now defined by combining histological patterns (classic, desmoplastic/nodular, extensive nodularity, anaplastic) and genetic hallmarks (WNT-activated; SHH-activated, TP53-mutant; SHH-activated, TP53-wildtype; non-WNT/non-SHH). Other newly recognized tumour entities include diffuse midline glioma, H3 K27M-mutant; ependymoma, RELA fusion-positive; and embryonal tumour with multilayered rosettes. The new classification is a significant step forward and will facilitate the development of novel targeted therapies of brain tumours.


Sign in / Sign up

Export Citation Format

Share Document